Cryoport Reports Q1 2026 Earnings with Revenue Growth and Expansion in Cell and Gene Therapy Services

Cryoport (CYRX) reported Q1 2026 earnings with total revenue of $47.8 million, a 16% year-over-year increase. The company saw growth in both commercial cell and gene therapy revenue and clinical trials revenue, with 766 global clinical trials supported at quarter-end. The report highlights continued expansion in its Life Sciences Services and Products segments.

By Motley Fool Transcribing · Motley Fool · May 4, 2026, 22:01 UTC

Tickers: $CYRX $RCKT

Topics: clinical trials commercial therapies earnings report pipeline activity revenue growth

Read the full article at Motley Fool

More World news

The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC